Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer

A compound of formula (I):

• wherein:
• is a substituted or unsubstituted N-containing monocyclic, bicyclic or tricyclic heteroraryl;
• R1 is H, an alkyl optionally substituted with one or two groups R6 or an aryl optionally substituted with one or more groups R6;
• R2 is H or alkyl;
• or
• R1 and R2 are bound together to form a 5- or 6-membered heterocycle;
• R3 and R4 are each independently H or an alkyl optionally substituted with one or two groups R6;
• or
• R3 and R4 are bound together to form a 5- to 8-membered heterocycle;
• R5 is H, a halogen, an alkyl optionally substituted with 1 or 2 groups R6, or an alkoxy optionally substituted with 1 or 2 groups R6;
• or
• R4 and R5 are bound together to form a 5- to 7-membered heterocyle;
• R6 is hydroxy, alkoxy, —NR15R16, —CO—Y—R17, —CN, —CF3, or aryl;
• R15 and R16 are each independently H, alkyl, —CO-alkyl or form together with the nitrogen atom a 3- to 6-membered cyclic group;
• Y is —O— or —NR18—;
• R17 is H or alkyl;
• and
• R18 is H, alkyl or hydroxyalkyl;
• provided that when R3 is H and R4 and R5 are bound together to form a 5-membered heterocycle, then R1 is not H;
• or a pharmaceutically acceptable salt thereof.